Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Genitourinary 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Caves × Tumor-Agnostic × Clear all
NCT04036045 2025-10-06

Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity

Connecticut Children's Medical Center

Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡